Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel versus active symptom control in relapsed gastric adenocarcinoma
ISRCTN13366390Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel in gastric adenocarcinoma and Esophago-Gastric Adenocarcinoma (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Overall survival. Started Apr 2008; status: completed.
02
Drugs
docetaxel
03
Conditions
gastric adenocarcinomaEsophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on ISRCTN13366390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13366390.